Parkinson's Disease/Movement Disorders News

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

An automated machine-learning method that analyzed sleep movements recorded with a conventional 2D camera may improve diagnosis of rapid eye movement sleep behavior disorder, according to a study published in Annals of Neurology.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues, data from JAMA Neurology show.

The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.

The Parkinson's Foundation has issued new recommendations to improve the standard of care for hospitalization among individuals with Parkinson’s disease.